Subsequently, Esteller et al., in an analysis of samples harvested from glioma patients treated with the alkylating agent carmustine (BCNU), demonstrated a correlation between MGMT promoter methylation and tumor response and overall survival (4). This evidence concerns the gene MGMT and neoplasm.